US stock · Healthcare sector · Drug Manufacturers—General

AbbVie Inc.

ABBV

NYSE

137.56

USD

-1.06

(-0.76%)

Market Closed

31.99P/E

13Forward P/E

1.33P/E to S&P500

242.696BMarket CAP

4.17%Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

27 Jul-31 Jul

Shares Short

5/15/23

11.97M

Short % of Float

0.68%

Short % of Shares Outs.

0.68%

% Held by Insiders

0.13%

% Held by Institutions

71.47%

Beta

0.55

PEG Ratio

-3.50

52w. high/low

168.11/134.09

Avg. Daily Volume

5.73M

Return %

Stock

S&P 500

1 year

(7.62)

2.11

3 years

51.85

38.05

5 years

35.74

54.53

Scale: |

High

Low

- -

54.78

33.33

70.76

45.50

71.60

45.45

68.12

50.71

99.10

59.27

125.86

77.50

92.30

62.66

109.15

62.55

136.83

101.81

175.91

128.26

168.11

137.10

Currency: USD

- -

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

- -

9.00

9.90

11.04

11.66

11.84

12.54

14.20

16.10

17.72

22.15

22.49

25.95

31.78

32.78

32.08

Earnings per share

- -

2.93

2.64

2.17

3.34

2.60

1.11

3.20

3.74

3.33

3.85

5.33

2.62

6.53

6.68

4.28

FCF per share

- -

3.20

2.87

3.73

3.81

3.64

1.85

4.35

4.12

5.92

8.65

8.64

9.51

12.44

13.69

13.40

Dividends per share

- -

1.61

1.67

2.05

2.33

2.58

3.77

4.30

4.37

5.24

5.67

5.75

CAPEX per share

- -

0.20

0.28

0.23

0.21

0.31

0.38

0.33

0.30

0.33

0.43

0.37

0.45

0.39

0.30

Book Value per sh.

- -

9.94

7.74

2.13

2.83

1.09

2.45

2.91

3.20

(5.71)

(5.53)

7.41

8.71

9.74

8.65

Comm.Shares outs.

- -

1,580

1,577

1,587

1,591

1,610

1,593

1,592

1,479

1,765

1,768

1,771

1,769

Avg. annual P/E ratio

- -

16.7

49.7

19.2

16.1

22.4

25.3

14.5

34.4

17.3

22.1

32.0

P/E to S&P500

- -

1.0

2.7

1.0

0.7

1.0

0.6

0.9

0.6

1.0

1.3

Avg. annual div. yield

- -

3.7%

3.0%

3.3%

3.9%

3.4%

3.9%

5.6%

4.9%

4.6%

3.8%

Revenue (m)

- -

14,214

15,638

17,444

18,380

18,790

19,960

22,859

25,638

28,216

32,753

33,266

45,804

56,197

58,054

56,741

Operating margin

- -

34.7%

30.2%

20.8%

31.6%

30.1%

17.1%

33.0%

36.6%

34.0%

19.5%

39.0%

24.8%

31.9%

32.4%

16.7%

Depreciation (m)

- -

697

1,184

1,272

1,150

897

786

836

1,189

1,501

1,765

2,017

6,471

8,521

8,467

6,749

Net profit (m)

- -

4,637

4,178

3,433

5,275

4,128

1,774

5,144

5,953

5,309

5,687

7,882

4,616

11,542

11,836

7,585

Income tax rate

- -

22.1%

13.6%

6.4%

7.9%

22.6%

25.1%

22.6%

24.5%

31.3%

(9.4)%

6.5%

(36.0)%

11.1%

12.1%

24.4%

Net profit margin

- -

32.6%

26.7%

19.7%

28.7%

22.0%

8.9%

22.5%

23.2%

18.8%

17.4%

23.7%

10.1%

20.5%

20.4%

12.8%

Working capital (m)

- -

4,457

1,457

8,578

10,969

4,688

5,420

6,406

4,582

(294)

33,934

(4,488)

(7,266)

(1,075)

(1,102)

Long-term debt (m)

- -

14,630

14,292

10,565

29,240

36,440

30,953

35,002

62,975

77,554

64,189

59,135

59,292

Equity (m)

- -

15,703

12,224

3,363

4,492

1,742

3,945

4,636

5,097

(8,446)

(8,172)

13,076

15,408

17,254

13,274

ROIC

- -

24.0%

24.9%

26.5%

19.5%

13.0%

13.5%

12.0%

11.3%

17.0%

13.0%

6.5%

12.3%

9.2%

6.6%

Return on capital

- -

22.9%

18.7%

21.6%

19.3%

10.2%

13.9%

13.5%

12.5%

11.0%

11.5%

3.9%

10.5%

8.2%

7.0%

Return on equity

- -

26.6%

28.1%

156.9%

91.9%

101.8%

130.4%

128.4%

104.2%

(67.3)%

(96.5)%

35.3%

74.9%

68.6%

57.1%

Plowback ratio

- -

100.0%

38.1%

(50.0)%

36.0%

37.6%

22.6%

1.9%

19.2%

(66.9)%

19.8%

15.2%

(34.0)%

Div.&Repurch./FCF

- -

49.8%

112.8%

155.1%

148.6%

58.5%

137.6%

54.8%

51.8%

46.4%

47.6%

51.0%

Capital Structure

5 May · 2023 | Q1

All numbers in millions

Total liabilities

$ 121,241

Total assets

$ 134,544

Long-term debt

$ 59,292

Cash and equiv.

$ 6,711

Goodwill

$ 32,220

Retained earnings

$ 2,393

Common stock

1,764

Enterprise Value

$ 295,277

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

8,479

9,830

9,229

Receivables

8,822

9,977

11,254

Inventory

3,310

3,128

3,579

Other

3,562

6,290

5,153

Current assets

24,173

27,928

28,463

Acc. Payable

2,276

2,882

- -

Debt due

8,502

12,495

4,136

Other

17,883

19,817

25,402

Current liabilities

28,661

35,194

29,538

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

3.30%

16.31%

13.81%

Cash flow

10.27%

18.14%

26.10%

Earnings

2.55%

37.44%

32.75%

Dividends

8.44%

15.94%

16.77%

Book value

11.98%

(58.36)%

(45.16)%

Insider Trading

Type

Date

Strom Carrie C

InKind

2,876

05/11/23

Waddell Frederick H

Award

1,450

05/05/23

Tilton Glenn F

Award

1,450

05/05/23

Roberts Rebecca B

Award

1,450

05/05/23

Rapp Edward J

Award

1,450

05/05/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

13,010

13,959

14,342

14,886

56,197

2022

13,538

14,583

14,812

15,121

58,054

2023

12,225

- -

Earnings per share

Currency: USD

Year

Total

2021

2.01

0.43

1.80

2.29

6.53

2022

2.54

0.52

2.23

1.40

6.68

2023

0.14

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

1.31

5.24

2022

1.43

1.42

1.41

1.42

5.67

2023

1.51

- -

Company Description

Sector:

Healthcare

Industry:

Drug Manufacturers—General

CEO:

Mr. Richard A. Gonzalez

Full-time employees:

50,000

City:

North Chicago

Address:

1 North Waukegan Road

IPO:

Jan 2, 2013

CIK:

0001551152

Website:

abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Powered by AI

AbbVie Inc.

137.56